Sign in
4

Changes in Ownership

Taysha Gene Therapies, Inc. Filed Acc 0001665124-26-000002

President and Head of R&D sold 200,000 shares at $4.71 ($942,000)

  • President and Head of R&D acquired 200,000 shares (option exercise)
  • President and Head of R&D acquired 427,000 shares (grant or award)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I
Nagendran Sukumar President and Head of R&D 2026-01-12 Option exercise 10b5-1 +111,324 $0.70 $77,804 1,117,763 D
Nagendran Sukumar President and Head of R&D 2026-01-12 Option exercise 10b5-1 +88,676 $1.71 $151,636 1,206,439 D
Nagendran Sukumar President and Head of R&D 2026-01-12 Sale 10b5-1 −200,000 $4.71 $942,000 1,006,439 D
Nagendran Sukumar President and Head of R&D 2026-01-12 Grant or award 10b5-1 +427,000 1,433,439 D
Derivatives
Nagendran Sukumar President and Head of R&D 2026-01-12 Option exercise · Employee Stock Option (right to buy) 10b5-1 −111,324 111,359 D
Nagendran Sukumar President and Head of R&D 2026-01-12 Option exercise · Employee Stock Option (right to buy) 10b5-1 −88,676 474,941 D
Nagendran Sukumar President and Head of R&D 2026-01-12 Grant or award · Employee Stock Option (right to buy) 10b5-1 +274,000 274,000 D
Open-market sales · 200,000 sh · avg $4.71 · $942,000
Loading xslF345X05/form4-01142026_040101.xml…